A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy versus 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy versus 8-week gliclazide (Sulfonylurea derivate), followed by 8-week gliclazide intensification therapy on r
Active, not recruitingNL-OMON48622
Vrije Universiteit Medisch CentrumAdult-onset diabetes
Type 2 Diabetes Mellitus
Start: 2017-12-12Target: 66Updated: 2024-02-28